Immune checkpoint blockers (ICBs), and specifically the use of antibodies against programmed cell death-1 (PD-1), programmed cell death ligand-1 (PD-L1), and cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) have been approved for use in several cancer types and demonstrated improved overall survival (OS) compared with the standard therapy (AstraZeneca Pharmaceuticals 2017; Bristol-Myers Squibb 2013; Bristol-Myers Squibb 2017; Genentech 2017; Merck and Company Inc. 2017; Pfizer 2017). Here, CTLA4 is linked to cancer.